Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

J&J Bullish On OTC Drug Pricing, Consumer Regard For Its Brands

This article was originally published in The Tan Sheet

Executive Summary

Brand strength, not price cuts, drives J&J OTC product sales, says Worldwide Group Chairwoman Sandra Peterson. The firm has returned 80% of its recalled brands to store shelves and will restart Tylenol Arthritis distribution later this year, leaving one “substantive” product to re-launch.


Related Content

Missing CAPA Costs J&J $25 Million In Investigation Sparked By OTC Recalls
J&J Bit Off More Than McNeil Could Chew In 2006 Pfizer OTC Acquisition
Lonely At The Top? Not In OTC Sector As Bayer, GSK/Novartis Challenge J&J


Related Companies